Basics CytomX Therapeutics, Inc. CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is engaged in developing antibody therapeutics based on probody technology platform. IPO Date: October 8, 2015 Sector: Healthcare Industry: Biotech Market Cap: $376M Activated in VL: True Average Daily Range Avg Daily Range: $0.25 | 2.99% Avg Daily Range (30 D): $0.09 | 4.41% Avg Daily Range (90 D): $0.10 | 4.99% Institutional Daily Volume Avg Daily Volume: .83M Avg Daily Volume (30 D): 2.99M Avg Daily Volume (90 D): 4.06M Trade Size Avg Trade Size (Sh.): 189 Avg Trade Size (Sh.) (30 D): 289 Avg Trade Size (Sh.) (90 D): 300 Institutional Trades Total Inst.Trades: 882 Avg Inst. Trade: $1.43M Avg Inst. Trade (30 D): $1.18M Avg Inst. Trade (90 D): $1.25M Avg Inst. Trade Volume: .2M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $1.6M Avg Closing Trade (30 D): $1.66M Avg Closing Trade (90 D): $2.24M Avg Closing Volume: 181.63K     News Aug 7, 2025 @ 10:29 PM CytomX (CTMX) Q2 Revenue Drops 26% Source: Na Jul 9, 2025 @ 12:30 PM Breaking Through: Systemic Genetic Medicines for H... Source: Prnewswire Apr 28, 2025 @ 8:00 PM CytomX Therapeutics Presents Preclinical Data for ... Source: Cytomx Therapeutics Mar 5, 2025 @ 1:00 PM CytomX Therapeutics to Present at the Barclays 27t... Source: N/A Jun 17, 2024 @ 8:15 PM CytomX Therapeutics Promotes Chris Ogden to Chief ... Source: CytomX Therapeutics Inc. Financials   TTM Q2 2025 Q1 2025 Basic EPS Diluted EPS Revenue $ 141.1M $ 18.66M $ 50.92M Gross Profit $ $ $ Net Income / Loss $ 47.98M $ -.15M $ 23.53M Operating Income / Loss $ 43.13M $ -1.29M $ 22.62M Cost of Revenue $ $ $ Net Cash Flow $ 5.91M $ 10.99M $ M PE Ratio